FSTL3 promotes colorectal cancer by activating the HIF1  pathway
This study highlights FSTL3's significance in CRC, linked to adverse outcomes and invasiveness, suggesting the HIF1 pathway mediates FSTL3's oncogenic functions, offering insights for targeting FSTL3 in CRC treatment.